AZD1419 phase II is a double blinded trial, its primary endpoint completion date is still a few days away. After the completion date, It would take another 4 to 6 weeks for data collection and analysis before reporting its trial result data(we are in hurry for AZD1419, but AZD is big company and AZD1419 is important to them, but not as much as AZD1419 to DVAX); therefore, we may have to wait to later Oct or earlier Nov for any related news
I am holding my shares for long, and short selling will not force me to give up my position. DVAX will worth more than $25 just by its H-B vaccine in another one year or one and half years once its revenue creating positive cash flow, not to mention its potential in oncology as well possible success from AZD1419.